Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic.
作者信息
Melmed Gil Y, Rubin David T, McGovern Dermot P B
机构信息
F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California.
University of Chicago Medicine Inflammatory Bowel Disease Center and, MacLean Center for Clinical Medical Ethics, Chicago, Illinois.
出版信息
Gastroenterology. 2021 Feb;160(3):639-644. doi: 10.1053/j.gastro.2020.10.013. Epub 2020 Oct 14.
Abstract
摘要
相似文献
1
Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic.寒冬将至！2019冠状病毒病大流行期间炎症性肠病患者疫苗接种的临床、免疫学及实际考量
Gastroenterology. 2021 Feb;160(3):639-644. doi: 10.1053/j.gastro.2020.10.013. Epub 2020 Oct 14.
2
The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.mRNA疫苗的世纪：新冠疫苗与过敏
J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):89-91. doi: 10.18176/jiaci.0665. Epub 2020 Jan 4.
3
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.炎症性肠病患者接受生物治疗时对SARS-CoV-2疫苗的接种情况。
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):989. doi: 10.1016/S2468-1253(21)00347-2. Epub 2021 Oct 14.
4
Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.炎症性肠病免疫抑制患者的严重急性呼吸综合征冠状病毒2型疫苗第三剂接种
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):987-988. doi: 10.1016/S2468-1253(21)00374-5. Epub 2021 Oct 13.
5
Parents' intent to vaccinate against influenza during the COVID-19 pandemic in two regions in Switzerland.瑞士两个地区父母在 COVID-19 大流行期间接种流感疫苗的意向。
Swiss Med Wkly. 2021 May 12;151:w20508. doi: 10.4414/smw.2021.20508. eCollection 2021 May 10.
6
Sub-optimal H1N1 vaccine uptake by immunocompromised inflammatory bowel disease patients.免疫功能低下的炎症性肠病患者对甲型H1N1流感疫苗的接种率欠佳。
Clin Med (Lond). 2011 Jun;11(3):301. doi: 10.7861/clinmedicine.11-3-301.
7
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy.在接受免疫调节剂和生物治疗的炎症性肠病患者的大型观察队列中使用 H1N1 疫苗。
Gut. 2011 Apr;60(4):456-62. doi: 10.1136/gut.2010.233981. Epub 2011 Jan 26.
8
Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial.加强型流感疫苗接种不能改善接受免疫抑制剂治疗的成年炎症性肠病患者的免疫反应：一项随机对照试验。
J Gastroenterol. 2015 Aug;50(8):876-86. doi: 10.1007/s00535-015-1042-7. Epub 2015 Feb 12.
9
Influenza Virus and SARS-CoV-2 Vaccines.流感病毒和 SARS-CoV-2 疫苗。
J Immunol. 2021 Jun 1;206(11):2509-2520. doi: 10.4049/jimmunol.2001287. Epub 2021 May 21.
10
[The efficiency of influenza vaccines in patients with inflammatory bowel disease on immunosuppressive therapy].[炎症性肠病患者接受免疫抑制治疗时流感疫苗的有效性]
Orv Hetil. 2012 Nov 25;153(47):1870-4. doi: 10.1556/OH.2012.29484.
引用本文的文献
1
Vaccination strategies for Korean patients with inflammatory bowel disease.韩国炎症性肠病患者的疫苗接种策略。
Korean J Intern Med. 2022 Sep;37(5):920-930. doi: 10.3904/kjim.2022.149. Epub 2022 Aug 8.
2
Effectiveness and Safety of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease.2019冠状病毒病疫苗在炎症性肠病患者中的有效性和安全性
Gastroenterol Hepatol (N Y). 2022 Mar;18(3):145-155.
3
Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.新型冠状病毒疫苗在炎症性肠病患者中的安全性：系统评价和荟萃分析。
Dig Liver Dis. 2022 Jun;54(6):713-721. doi: 10.1016/j.dld.2022.03.005. Epub 2022 Mar 22.
4
SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID.针对成年炎症性肠病患者的新型冠状病毒2型疫苗接种：韩国炎症性肠病学会专家共识声明
Intest Res. 2022 Apr;20(2):171-183. doi: 10.5217/ir.2021.00098. Epub 2022 Jan 5.
5
COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology.**新冠疫情在消化科领域的现状：我们现在了解多少？**
**新冠疫情对消化科影响的现有证据**。
United European Gastroenterol J. 2021 Sep;9(7):750-765. doi: 10.1002/ueg2.12115. Epub 2021 Jun 30.
6
How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.如何管理免疫介导的炎症性疾病中的新冠疫苗接种：免疫介导的炎症性疾病研究组的专家意见
Front Immunol. 2021 Apr 15;12:656362. doi: 10.3389/fimmu.2021.656362. eCollection 2021.
7
Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.在全球 2019 冠状病毒病大流行期间优化炎症性肠病的管理。
Curr Opin Gastroenterol. 2021 Jul 1;37(4):313-319. doi: 10.1097/MOG.0000000000000741.
8
Reply.回复。
Gastroenterology. 2021 Jun;160(7):2627. doi: 10.1053/j.gastro.2021.02.012. Epub 2021 Feb 7.
9
SARS-CoV-2 vaccination in IBD: more pros than cons.SARS-CoV-2 疫苗接种在 IBD 中的应用：利大于弊。
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):211-213. doi: 10.1038/s41575-021-00420-w.
10
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.炎症性肠病患者的新型冠状病毒2型疫苗接种：一项国际共识会议的建议
Gut. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20.
本文引用的文献
1
Fairly Prioritizing Groups for Access to COVID-19 Vaccines.合理确定获得新冠疫苗的优先群体
JAMA. 2020 Oct 27;324(16):1601-1602. doi: 10.1001/jama.2020.18513.
2
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.两种配方的基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和免疫原性：来自俄罗斯的两项开放、非随机的 1/2 期研究。
Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4.
3
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗：全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
4
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.接受细胞因子抑制剂治疗的免疫介导性炎症性疾病患者 SARS-CoV-2 血清转化发生率较低。
Nat Commun. 2020 Jul 24;11(1):3774. doi: 10.1038/s41467-020-17703-6.
5
BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).BCG 疫苗可预防严重的 2019 年冠状病毒病（COVID-19）。
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17720-17726. doi: 10.1073/pnas.2008410117. Epub 2020 Jul 9.
6
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.皮质类固醇，而不是 TNF 拮抗剂，与炎症性肠病患者 COVID-19 不良结局相关：来自国际登记处的结果。
Gastroenterology. 2020 Aug;159(2):481-491.e3. doi: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18.
7
Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.高剂量流感疫苗对接受抗TNF单药治疗的炎症性肠病患者的免疫原性：一项随机临床试验。
Inflamm Bowel Dis. 2020 Mar 4;26(4):593-602. doi: 10.1093/ibd/izz164.
8
Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012-2015.2012-2015 年新西兰成人中流感疫苗预防与流感相关的重症监护病房入院和减轻严重疾病的效果。
Vaccine. 2018 Sep 18;36(39):5916-5925. doi: 10.1016/j.vaccine.2018.07.028. Epub 2018 Aug 1.
9
Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease.140480 例炎症性肠病患者流感及流感相关并发症风险增加。
Inflamm Bowel Dis. 2019 Jan 10;25(2):369-376. doi: 10.1093/ibd/izy243.
10
Influenza vaccine failure: failure to protect or failure to understand?流感疫苗失效：是未能保护还是未能理解？
Expert Rev Vaccines. 2018 Jun;17(6):495-502. doi: 10.1080/14760584.2018.1484284. Epub 2018 Jun 26.
Zotero 插件